Experience

Marya Postner

    • Forbius Agrees to Sell to Bristol Myers Squibb 


    • Sangamo Announces Global Collaboration with Novartis 


    • Sangamo Announces Global Licensing Collaboration Agreement with Biogen 


    • Jazz Pharma Announces Exclusive License Agreement with PharmaMar 


    • Iconic Therapeutics Announces Option and License Agreement with Exelixis 


    • GTx Announces Reverse Merger with Oncternal Therapeutics 


    • Triphase Accelerator Corporation in its Partnership and Option-to-acquire Arrangement with Celgene 


    • Tetra Discovery Partners in its Strategic Collaboration with Shionogi 


    • Kineta Announces Collaboration with Pfizer 


    • Compact Imaging Announces Collaboration with Novartis 


    • Sangamo Announces Collaboration with Kite 


    • Sangamo Announces Collaboration with Pfizer 


    • Jazz Pharmaceuticals' Strategic Collaboration and Option Agreement with ImmunoGen 


    • Sangamo Announces Collaboration and License Agreement with Pfizer 


    • Bristol Meyers Enters Agreement with Five Prime 


    • NGM Announces Collaboration with Merck 


    • NewLink Genetics Signs $1 Billion Deal with Genentech for Cancer Drug Research & Development 


    • BioMarin Pharmaceutical in its Licensing Agreement with Allievex Group 


    • OnCore Biopharma Announces Merger Agreement with Tekmira Pharmaceuticals 


    • Iconic Therapeutics Series C Financing 


    • Alder Biopharmaceuticals $80 Million Initial Public Offering 


    • Medivation Expanding Oncology Franchise with Acquisition of Talazoparib from BioMarin 


    • Axovant Completes $362 Million IPO 


    • BioMarin $10 Million Acquisition of Zacharon 


    • Jazz Pharmaceuticals Acquires Celator for $1.5 Billion 


    • Jazz Pharmaceuticals $125 Million Acquisition of ADX-N05 


    • Jazz Pharmaceuticals Acquisition of Redx Pharma's pan-RAF Inhibitor Program Valued up to $206 Million 


    •  


    • Five Prime Therapeutics Announces Collaboration with Zai Lab 


    • Miragen Therapeutics Announces Collaboration with Servier 


    • Lyell Immunopharma – $425 Million IPO 


    • Prothena Agrees to Sell ATTR Amyloidosis Program to Novo Nordisk